The prognostic value of lymph nodes mRNA CXCL12 expression in the breast cancer

Idha Safitri(1*), Irianiwati Widodo(2), Didik Setyo Heriyanto(3)

(1) Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta
(2) Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
(3) Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
(*) Corresponding Author


Prognosis of breast carcinoma is influenced by age, tumor size, histological grade and type, lymph node status, as well as metastasic status. Chemokine receptor CXCR-4 with its ligand, CXCL-12, may play an important role in metastasis of breast carcinoma. However, the role of CXCL-12 mRNA as a prognostic factor and a therapeutic target of human breast cancer remains controversial. This study aimed to investigate the level of CXCL-12 mRNA expression in lymph nodes of patients with invasive ductal breast carcinoma and the difference within the prognostic factors. Axillary lymph nodes obtained from 50 cases of invasive ductal breast carcinoma, were divided into two groups, with and without lymph node metastasis. Each group consisted of 25 cases. Total RNA was extracted from formalin-fixed paraffin-embedded. The CXCL-12 mRNA expression was examined using qRT-PCR method. The mean differences between the two groups were analyzed using Mann-Whitney test. The differences between CXCL-12 mRNA expression and each prognostic factor ware analyzed using Mann-Whitney comparison test. CXCL-12 mRNA expression was significantly higher in the lymph node of patients with metastasis of breast carcinoma compared to the non-metastasis cases (p<0.01). There were significant differences between CXCL-12 mRNA expression with poorly histological grade (p=0.003), bigger primary tumor size (p=0.005) and age of ≥45 y.o (p=0.012) in the metastatic group, but there were no significant differences between both age of <45 and ≥45 y.o.This study suggests that the higher CXCL-12 mRNA expression level are associated with bigger tumor size and poor differentiation in breast cancer patient with lymph nodes metastasis



breast carcinoma; CXCL-12 mRNA expression; lymph nodes; metastasis; prognostic factor;

Full Text:



  1. Kementrian Kesehatan RI. Profil kesehatan Indonesia. InfoDatin, Pusat Data dan Informasi Kemenkes RI, 2015.
  2. World Health Organization. Global health observatory. Geneva: World Health Organization, 2018.
  3. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumors of the breast, 4th ed. Lyon: IARC, 2012.
  4. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006; 238(1):30-41.
  5. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, et al. Regulation of cellularproliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002; 62(21):6304-11.
  6. Adams GB, Chabner KT, Foxall RB, Weibrecht KW, Rodrigues NP, Dombkowski D, et al. Heterologous cells cooperate to augment stem cell migration, homing, and engraftment. Blood 2003; 101(1):45-51.
  7. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10(8):858-64.
  8. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR 4 by hypoxia. J Exp Med 2003; 198(9):1391-402.
  9. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancer: potential regulation by ligan-dependent degradation and HIF-1α. Biochem Biophys Res Commun 2006; 346(1):252-8.
  10. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, et al. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 2009; 45(14):2579-87.
  11. Sun Y, Mao X, Fan C, Liu C, Guo A, Guan S, et al. CXCL12- CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumor Biol 2014; 35(8):7765-73.
  12. Liu H, Li Z, Deng M, Liu Q, Zhang T, Guo W, et al. Prognostic and clinicopathological value of CXCL12/SDF1 expression in breast cancer: a meta analysis. Clin Chim Acta 2018; 484:72-80.
  13. Orimo A, Gupta PB, Sgroi DC, Seisdedos FA, Daleunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF1/CXCL12 secretion. Cell 2005; 121(3):335-48.
  14. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002; 277(51):49481-7.
  15. Mottet AM, Liberman J, Ascencao K, Flahaut M, Bourloud KB, Yan P, et al. The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell Homing. PloS One 2015; 10(5):0125616.
  16. Amara S, Chaar I, Khiari M, Ounissi D, Weslati M, Bouqhriba R, et al. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis. Cancer Biomark 2015; 15(6):869-79.
  17. Dehghani M, Kianpour S, Zangeneh A, Pour ZM. CXCL12 modulates prostate cancer cell adhesion by altering the levels or activities of β1-containing integrins. Int J Cell Biol 2014; 2014:981750.
  18. Bi J, Li P, Li C, He J, Wang Y, Zhang H, et al. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration. Tumour Biol 2016; 37(3):4175-82.
  19. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, et al. The chemokine CXCL12 is an independent predictor of poor survival in ovarian cancer. Br J Cancer 2012; 106(7):1306-13.
  20. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 239(12):2744-53.
  21. Zhao BC, Wang ZJ, Mao WZ, Ma HC, Han JG, Zhao B, et al. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 2011; 17(19):2389-96.
  22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods 2001; 25(4):402-8.
  23. Kashofer K, Viertler C, Pichler M, Zatloukal K. Quality control of RNA preservation and extraction from paraffin-embadded tissue: implications for RT-PCR and microarray analysis. PloS ONE 2013; 8(7):70714.
  24. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824):50-6.
  25. Kang H, Watkins G, Parr C, Jones AD, Mansel RE, Jing WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005; 7(4):402-10.
  26. Hirakawa S, Detmar M, Kerjaschki D, Nagamatsu S, Matsuo K, Tanemura A, et al. Nodal lymphangiogenesis and metastasis: Role of tumor-induced lymphatic vessel activation in extramammary Paget’s disease. Am J Pathol 2009; 175(5):2235-48.
  27. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann NY Acad Sci 2008; 1131(1):225-34.
  28. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by sromal-derived factor-1α. Am J Pathol 1999; 154(4):1125-35.
  29. Schnitt SJ and Guidi AJ. Pathology of invasive breast cancer. In: Harris JR, Lippmann ME, Morrow M, Osborne CK eds. Disease of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000; pp.425-70.
  30. Kumar V, Abbas AK, Aster JC. Robbins basic pathology, 9th ed. Philadelphia: Elsevier Saunders, 2013.
  31. Chang JC, Hilsenbeck SG. Staging of the breast. In: Harris JR, Lippman ME, Morrow M,Osborne CK eds. Disease of the breast, 4th edition. Philadelphia PA: Lippincott Williams & Wilkins, 2010.
  32. Kim JO, Suh KS, Lee DH, Sul HJ, Lee JU, Song KS. Expression of CXCR4 and SDF-1α in primary breast cancer and metastatic lymph node. J Breast Cancer 2009; 12(4):249-56.
  33. McPherson K, Steel CM, Dixon JM. ABC of breast disease: breast cancer epidemiology, risk factors and genetics. BMJ 2000; 321(7261):624-8.
  34. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP, et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 2000; 53(10):778-83.
  35. Mousa NA, Casper RF. Menopausal estrogen deprivation activates steroid sensitive stem cells (3SC) and local estrogen biosynthesis: a model for breast cancer development. Biosci Hypotheses 2009; 2(4):252-6.
  36. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003; 17(5):792-803.
  37. Fan Z, Li J, Wang T, Xie Y, Fan T, Lin B, et al. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemoterpi. Breast 2013; 22(6):1161-5.


Article Metrics

Abstract views : 1178 | views : 1687

Copyright (c) 2019 idha safitri, Irianiwati Widodo, Didik Setyo Heriyanto

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats


Creative Commons License
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by  Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at